Our lastest news on Orsiro and Orsiro Mission DES
05
July
2022
|
10:14
Europe/Amsterdam
A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (
28
February
2022
|
14:27
Europe/Amsterdam
BIOTRONIK Sets New Clinical Benchmark with Ultrathin Strut Orsiro Coronary Drug-Eluting Stent
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro’s Position as the Clinical Benchmark for DES
BIOTRONIK today announced five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking-clinical-trial session by Dr. David Kandzari, US …
30
September
2021
|
10:35
Europe/Amsterdam
Press Release: FDA Approval and First Implant of Orsiro Mission Drug-Eluting Stent System in the U.S.
Full Commercial Launch Underway for the Latest Generation of BIOTRONIK’s Ultrathin Strut DES, Providing Advanced Deliverability for the outstanding Orsiro DES
BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The company also …
22
March
2021
|
11:13
Europe/Amsterdam
Superioridad del DES Orsiro frente al DES Xience confirmada en pacientes STEMI
En el estudio clínico BIOSTEMI, concebido para demostrar superioridad, se confirma que Orsiro es un stent farmacoactivo (DES, por sus siglas en inglés) superior para STEMI en el seguimiento a dos años
El stent de strut ultrafino de BIOTRONIK, Orsiro, ha demostrado ser superior al DES Xience en cuanto al fallo de la lesión tratada (TLF) a los 24 meses según los nuevos datos del seguimiento del …
15
March
2021
|
14:42
Europe/Amsterdam
Superiority of Orsiro DES Over Xience DES Confirmed in STEMI Patients
In the BIOSTEMI clinical trial, powered for superiority, Orsiro is confirmed as the superior drug-eluting stent (DES) for STEMI at two-year follow-up
BIOTRONIK’s ultrathin-strut stent, Orsiro, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.The latest …
06
May
2020
|
09:24
Europe/Amsterdam
TICO Randomized Controlled Trial Establishes Safety and Efficacy of Ticagrelor Monotherapy Alone in ACS Patients Treated with Ultrathin Drug-Eluting Stent Orsiro
New Outcomes on Short DAPT Show Benefit in ACS Patients
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro drug eluting stent (DES) benefit from stopping aspirin three months after …